Do the States/FDA now have the juice to come for Grey?

[QueenMuntha]

This piece, penned by "The Peptide List", leans toward melodrama and seems crafted mainly to pull traffic toward his Peptide site. Even so, once you factor all that in, it still raises a concern I find legitimate. It does speak the truth. It covers not just the 503B pharmacy crackdown, but also China sources and mail distribution.

Setting the Compounding Pharmacy side apart, Connecticut's step to choke off Chinese suppliers stands out as noteworthy:

The State Lane: Connecticut Closes a Marketplace​On May 6, 2026, the same morning Novo Nordisk reported its first quarter, Connecticut Attorney General William Tong announced a settlement with Made-in-China. Made-in-China is an international trade platform that hosts third-party listings for manufacturers, primarily in China, marketing products into the United States and other Western economies. Among the listings, Tong’s office found, were vial-strength bulk semaglutide and tirzepatide and other GLP-1 receptor agonists, marketed as research chemicals or as bulk active pharmaceutical ingredient, with shipping to U.S. addresses available.

The settlement requires Made-in-China to cease all GLP-1 sales to U.S. customers, deploy a monitoring system to detect and remove future listings, and remove any GLP-1 listing within five days of identification. The platform agreed to a $300,000 penalty, suspended after a $30,000 payment, with the suspended balance contingent on compliance.

Click to expand...

Worth the read. It is on suspicious-link-removed by "The Peptide List's suspicious-link-removed".

More information from this subReddit post:

View: https://www.reddit.com/r/tirzepatidecompound/comments/1tb4rbb/prorx_warning_letter_looks_like_prorx_was_telling/

 

[gusterbuster]

Hmm, I'm curious whether vendors will have to take GLPs off their price lists, and then we request quotes for GLPs. That way they aren't listed and the forum can't be fined.

 

[lessthanhalf]

Made in China is a fairly big e-commerce site, mostly for wholesale buyers rather than retail ones, which means US authorities can legally go after it. This sort of action could hit compounders who purchase in bulk from china, though by now most of them probably have direct chinese contacts and don't rely on the platform, or they can use smaller resellers when necessary. Their profit margins are huge, so paying slightly more changes nothing. Finding GLP's on alibaba or alibaba express is already difficult. I'm certain there are other Chinese ecommerce platforms I'm unaware of.

Small scale vendors who work through email, discord or telegram simply cannot be reached by those kinds of US legal measures, and they are small, very cheap to set up, and easy to replace when needed. For a vendor, getting shut down only costs them an established name and the customer goodwill attached to it, which is not trivial, but starting over under a new name is simple and costs almost nothing.

Should the Chinese government target them, that would be a different matter.

 

[CNCCurrency]

QueenMuntha said:

This piece, penned by "The Peptide List", leans toward melodrama and seems crafted mainly to pull traffic toward his Peptide site. Even so, once you factor all that in, it still raises a concern I find legitimate. It does speak the truth. It covers not just the 503B pharmacy crackdown, but also China sources and mail distribution.

Setting the Compounding Pharmacy side apart, Connecticut's step to choke off Chinese suppliers stands out as noteworthy:

The State Lane: Connecticut Closes a Marketplace​On May 6, 2026, the same morning Novo Nordisk reported its first quarter, Connecticut Attorney General William Tong announced a settlement with Made-in-China. Made-in-China is an international trade platform that hosts third-party listings for manufacturers, primarily in China, marketing products into the United States and other Western economies. Among the listings, Tong’s office found, were vial-strength bulk semaglutide and tirzepatide and other GLP-1 receptor agonists, marketed as research chemicals or as bulk active pharmaceutical ingredient, with shipping to U.S. addresses available.

The settlement requires Made-in-China to cease all GLP-1 sales to U.S. customers, deploy a monitoring system to detect and remove future listings, and remove any GLP-1 listing within five days of identification. The platform agreed to a $300,000 penalty, suspended after a $30,000 payment, with the suspended balance contingent on compliance.

Click to expand...

Worth the read. It is on suspicious-link-removed by "The Peptide List's suspicious-link-removed".

More information from this subReddit post:

View: https://www.reddit.com/r/tirzepatidecompound/comments/1tb4rbb/prorx_warning_letter_looks_like_prorx_was_telling/

What bearing does this have on grey China?

 

[gusterbuster]

CNCCurrency said:

QueenMuntha said:

This piece, penned by "The Peptide List", leans toward melodrama and seems crafted mainly to pull traffic toward his Peptide site. Even so, once you factor all that in, it still raises a concern I find legitimate. It does speak the truth. It covers not just the 503B pharmacy crackdown, but also China sources and mail distribution.

Setting the Compounding Pharmacy side apart, Connecticut's step to choke off Chinese suppliers stands out as noteworthy:

The State Lane: Connecticut Closes a Marketplace​On May 6, 2026, the same morning Novo Nordisk reported its first quarter, Connecticut Attorney General William Tong announced a settlement with Made-in-China. Made-in-China is an international trade platform that hosts third-party listings for manufacturers, primarily in China, marketing products into the United States and other Western economies. Among the listings, Tong’s office found, were vial-strength bulk semaglutide and tirzepatide and other GLP-1 receptor agonists, marketed as research chemicals or as bulk active pharmaceutical ingredient, with shipping to U.S. addresses available.

The settlement requires Made-in-China to cease all GLP-1 sales to U.S. customers, deploy a monitoring system to detect and remove future listings, and remove any GLP-1 listing within five days of identification. The platform agreed to a $300,000 penalty, suspended after a $30,000 payment, with the suspended balance contingent on compliance.

Click to expand...

Worth the read. It is on suspicious-link-removed by "The Peptide List's suspicious-link-removed".

More information from this subReddit post:

View: https://www.reddit.com/r/tirzepatidecompound/comments/1tb4rbb/prorx_warning_letter_looks_like_prorx_was_telling/

What bearing does this have on grey China?

Does that mean forums such as this one, which serve as venues for GLPs, could be pursued and fined by regulators?

 

[birdwhacker]

gusterbuster said:

CNCCurrency said:

QueenMuntha said:

This piece, penned by "The Peptide List", leans toward melodrama and seems crafted mainly to pull traffic toward his Peptide site. Even so, once you factor all that in, it still raises a concern I find legitimate. It does speak the truth. It covers not just the 503B pharmacy crackdown, but also China sources and mail distribution.

Setting the Compounding Pharmacy side apart, Connecticut's step to choke off Chinese suppliers stands out as noteworthy:

The State Lane: Connecticut Closes a Marketplace​On May 6, 2026, the same morning Novo Nordisk reported its first quarter, Connecticut Attorney General William Tong announced a settlement with Made-in-China. Made-in-China is an international trade platform that hosts third-party listings for manufacturers, primarily in China, marketing products into the United States and other Western economies. Among the listings, Tong’s office found, were vial-strength bulk semaglutide and tirzepatide and other GLP-1 receptor agonists, marketed as research chemicals or as bulk active pharmaceutical ingredient, with shipping to U.S. addresses available.

The settlement requires Made-in-China to cease all GLP-1 sales to U.S. customers, deploy a monitoring system to detect and remove future listings, and remove any GLP-1 listing within five days of identification. The platform agreed to a $300,000 penalty, suspended after a $30,000 payment, with the suspended balance contingent on compliance.

Click to expand...

Worth the read. It is on suspicious-link-removed by "The Peptide List's suspicious-link-removed".

More information from this subReddit post:

View: https://www.reddit.com/r/tirzepatidecompound/comments/1tb4rbb/prorx_warning_letter_looks_like_prorx_was_telling/

What bearing does this have on grey China?

Does that mean forums such as this one, which serve as venues for GLPs, could be pursued and fined by regulators?

Sure, that's within their power. Fortunately, whoever runs this place has more sense, and set up the web infrastructure so that it can't be traced back to him and can't be taken offline. The hosting is probably in some jurisdiction with reasonable regulations.

It goes without saying that a lot of what gets posted here breaks the law. So then—what's their next move?

 

[Smiter]

Yes. If a state decides to act, it has the ability. During the drug war, efforts struck the whole supply chain, yet most enforcement landed on the final tier—the user. Consider it as a purely hypothetical scenario: reflect on everything the state forbids from coming in, even something as extreme as a nuclear weapon. That shows that when it wants to, it can gather whatever resources are necessary to accomplish the job. Whether it actually follows through is a separate matter.

 

[CMA Pooky]

Yes, because Big Pharma owns the FDA, at some point there will be additional crackdowns and stricter enforcement.

 

[mybodyisasewer]

birdwhacker said:

gusterbuster said:

CNCCurrency said:

QueenMuntha said:

This piece, penned by "The Peptide List", leans toward melodrama and seems crafted mainly to pull traffic toward his Peptide site. Even so, once you factor all that in, it still raises a concern I find legitimate. It does speak the truth. It covers not just the 503B pharmacy crackdown, but also China sources and mail distribution.

Setting the Compounding Pharmacy side apart, Connecticut's step to choke off Chinese suppliers stands out as noteworthy:

The State Lane: Connecticut Closes a Marketplace​On May 6, 2026, the same morning Novo Nordisk reported its first quarter, Connecticut Attorney General William Tong announced a settlement with Made-in-China. Made-in-China is an international trade platform that hosts third-party listings for manufacturers, primarily in China, marketing products into the United States and other Western economies. Among the listings, Tong’s office found, were vial-strength bulk semaglutide and tirzepatide and other GLP-1 receptor agonists, marketed as research chemicals or as bulk active pharmaceutical ingredient, with shipping to U.S. addresses available.

The settlement requires Made-in-China to cease all GLP-1 sales to U.S. customers, deploy a monitoring system to detect and remove future listings, and remove any GLP-1 listing within five days of identification. The platform agreed to a $300,000 penalty, suspended after a $30,000 payment, with the suspended balance contingent on compliance.

Click to expand...

Worth the read. It is on suspicious-link-removed by "The Peptide List's suspicious-link-removed".

More information from this subReddit post:

View: https://www.reddit.com/r/tirzepatidecompound/comments/1tb4rbb/prorx_warning_letter_looks_like_prorx_was_telling/

What bearing does this have on grey China?

Does that mean forums such as this one, which serve as venues for GLPs, could be pursued and fined by regulators?

Sure, that's within their power. Fortunately, whoever runs this place has more sense, and set up the web infrastructure so that it can't be traced back to him and can't be taken offline. The hosting is probably in some jurisdiction with reasonable regulations.

It goes without saying that a lot of what gets posted here breaks the law. So then—what's their next move?

The WSJ will fill 3 more pages with bellyaching.

 

[spanky2026]

CMA Pooky said:

Yes, because Big Pharma owns the FDA, at some point there will be additional crackdowns and stricter enforcement.

That is, if they can hold onto an FDA director for longer than 90 seconds.